All In Biotech

Drug Trial Radar · NCT06646289

A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)

An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recombinant Adeno-associated Virus Vector (AAV5 hRKp.RPGR) for Gene Therapy of Adults and Children With X-linked Retinitis Pigmentosa Owing to Defects in Retinitis Pigmentosa GTPase Regulator (RPGR)

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

24

Actual

Start

Oct 10, 2024

Primary completion

Oct 24, 2030

Study completion Oct 24, 2030

Sponsor

Lead sponsor
MeiraGTx Ocular UK LtdIndustry
Sponsor type
Industry
First posted
Oct 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and tolerability of subretinal delivery of Adeno-associated Virus Vector (AAV5 hRKp.RPGR) gene therapy in adults and children with X-linked retinitis pigmentosa.

Conditions

  • X-Linked Retinitis Pigmentosa

Interventions

  • AAV5-hRKp.RPGRBiological

    AAV5-hRKp.RPGR will be administered sub-retinally.

  • No intervention (Follow-Up assessment)Other

    Participants will not receive any intervention and will undergo follow-up assessment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AE)Time frame: From baseline up to 5.5 years
  2. Change from Baseline in Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart Letter ScoresTime frame: Baseline, Months 12, 24, 36, 48 and 60
  3. Change from Baseline in Low Luminance Visual Acuity (LLVA) by ETDRS Chart Letter ScoreTime frame: Baseline, Months 12, 24, 36, 48 and 60

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Massachusetts Eye and Ear Infirmary

    Boston, Massachusetts

  • University of Michigan Kellogg Eye Center

    Ann Arbor, Michigan

  • Moorfields Eye Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.